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antagonists may increase the incidence of heart failure when used as monotherapy for hypertension. (See "Choice of therapy in primary (essential) hypertension: Recommendations", section on 'Alpha blockers'.) Tamsulosin, alfuzosin, and silodosin have lower potential to cause hypotension and syncope than either terazosin or doxazosin [15, [25] [26] [27] , and tamsulosin may further have slightly less effect on blood pressure than alfuzosin [23] . These differential effects on blood pressure by different alpha-1-antagonists may be due to their differential blocking of alpha-1A receptor subtype [28] . (See 'Mechanism' above.)
The hypotensive effects of terazosin and doxazosin can be potentiated by concomitant use of the phosphodiesterase-5 (PDE-5) inhibitors sildenafil or vardenafil. The risks with tadalafil are less clear. We feel that men who are on lower doses of terazosin or doxazosin and are not experiencing orthostatic blood pressure changes can be treated with PDE-5 inhibitors as long as dosing is separated by at least four hours. Tamsulosin at a dose of 0.4 mg/day does not appear to significantly potentiate the hypotensive effects of sildenafil [29] .
Other common side effects of alpha-1-antagonists include asthenia and nasal congestion. Tamsulosin and silodosin, in particular, can affect ejaculation. In one study, tamsulosin decreased mean ejaculate volume in more than 90 percent of patients, with 35 percent having no ejaculate; this problem was not observed with alfuzosin 10 mg [30] . Silodosin produces retrograde ejaculation in approximately 28 percent of patients [27] .
5-alpha-reductase inhibitors -There are two 5-alpha-reductase inhibitors approved in the United States, finasteride and dutasteride.
Mechanism -These drugs act by reducing the size of the prostate gland. Treatment for 6 to 12 months is generally needed before prostate size is sufficiently reduced to improve symptoms. The type 2 form of 5-alpha-reductase catalyzes the conversion of testosterone to dihydrotestosterone in the prostate, hair follicles, and other androgen-sensitive tissues. Its clinical importance is suggested by the observation that men with inactivating mutations of the gene for the enzyme have very small prostate glands and do not develop BPH [31] . The type 1 form of the enzyme is present in liver, non-genital skin, and some areas of the brain [32] .
Efficacy -In a multicenter trial 895 men with BPH were treated with placebo or 1 or 5 mg/day of finasteride for 12 months [33] . The following benefits were noted in the men treated with finasteride: Serum dihydrotestosterone concentrations decreased by about 70 percent and serum testosterone concentrations increased by 10 percent in both finasteride treatment groups.
A reduction in obstructive and non-obstructive symptom scores by 23 and 18 percent, respectively, in the men given 5 mg daily but less in the men given 1 mg daily and none in the men given placebo.
An increase in maximal urinary flow rate of 1.6 mL/sec in the men given 5 mg/day versus 1.4. mL/sec with 1 mg/day, and 0.2 mL/sec with placebo. The baseline value was approximately 7.3 mL/sec; values above 15 mL/sec are usually associated with no obstructive symptoms.
A reduction in mean prostatic volume by 19 and 18 percent in the two treatment groups versus 3 percent in the placebo group.
The efficacy of finasteride appears to persist with long-term treatment. As an example, a trial of over 3000 men who were treated daily with 5 mg of finasteride or placebo demonstrated that the improvements in symptom scores, maximal urinary flow rates, and prostate volume were maintained for more than four years [34] . The most important findings were that finasteride treatment decreased the probability of surgery (5 versus 10 percent, risk reduction 55 percent) and acute urinary retention (3 versus 7 percent, risk reduction 57 percent) (figure 2). Patients who remained on finasteride for six years in an open-label extension of the study had sustained benefits [35] .
The efficacy of finasteride is greater in men with larger prostate volumes than in men with smaller prostate volumes. (See 'Short-term efficacy' below.) Finasteride increases the apoptotic index of epithelial and stromal cells [36] and decreases the volume of epithelium [37] . After 12 months of treatment finasteride also decreases detrusor pressure at maximum flow rates in men with larger prostate glands (>40 mL) [38] .
Finasteride also may suppress gross hematuria in those in whom other causes (particularly prostate and bladder cancer) have been ruled out [39, 40] . In a randomized trial, 57 men with BPH, evidence of bleeding from friable prostatic tissue on flexible cystoscopy, and chronic intermittent gross hematuria with no other identifiable cause were assigned to finasteride or a control arm [39] . Finasteride was associated with a lower rate of recurrent hematuria (14 versus 63 percent) and of surgery for bleeding (0 versus 26 percent).
Dutasteride is an inhibitor of both 5-alpha reductase enzymes and may be more potent than finasteride. In a trial in 4325 men with BPH, dutasteride reduced the risk of acute urinary retention by 57 percent and surgical intervention by 48 percent, and also reduced prostate volume and symptoms after 24-month follow-up [41] . A subsequent trial found similar results after 48-month follow-up in men with BPH randomly assigned to dutasteride, compared to placebo [42] .
The Enlarged Prostate International Comparator Study (EPICS), an industry-sponsored trial, compared treatment with finasteride or dutasteride for 12 months [43] . The primary outcome reported, reduction in prostate volume, was not significantly different for the two drugs, although this outcome may not have clinical significance. The drugs were also not significantly different in the secondary endpoints of urinary flow rate and urinary symptom scores, and adverse effects were similar.
The 5-alpha-reductase inhibitors are more effective in men with larger prostates, and their effects on acute urinary retention and reduction in need for surgery require chronic treatment for more than a year. Dosing -Unlike with alpha antagonists, dosing with 5-alpha-reductase inhibitors do not require titration. Finasteride can be initiated and maintained at 5 mg once daily. Similarly, dutasteride can be initiated and maintained at 0.5 mg once daily.
Side effects -The major side effects of these drugs are decreased libido and ejaculatory or erectile dysfunction. These occurred in 4 to 6 percent of men in a randomized trial of finasteride [33] . Rates of sexual dysfunction in a primary care trial of finasteride were somewhat higher (13.8 percent for any sexual adverse event) [44] , and this may be more reflective of clinical practice. However, in a long-term trial of finasteride versus placebo in 3040 men with BPH, adverse sexual effects were increased only during the first year of therapy [45] .
Serum prostate-specific antigen (PSA) concentrations decrease by about 50 percent [33] , a change that must be kept in mind in interpreting the results of serum PSA measurements in men treated with this drug [46] . Findings from the Prostate Cancer Prevention Trial suggest that PSA values be corrected by a factor of 2 for the first 24 months of finasteride use, and by a factor of 2.5 for longer term use [47] . (See "Measurement of prostate specific antigen", section on 'Benign prostatic hyperplasia'.)
Finasteride does not cause loss of bone [48] , perhaps because serum estradiol concentrations do not change. A case-control study found no positive association between use of finasteride and hip fracture, and actually found some evidence of lower risk of fracture with finasteride use [49] .
In randomized trials, 5-alpha-reductase inhibitors significantly decrease the incidence of prostate cancer. However, concern has been raised about whether 5-alpha-reductase inhibitors increase the incidence of high-grade lesions, although many believe this finding is spurious. This is discussed in detail separately. (See "Chemoprevention strategies in prostate cancer", section on '5-Alpha reductase inhibitors'.)
The United States Food and Drug Administration (FDA) recommends that before starting 5-alpha reductase inhibitors for treatment of BPH, the patient should be assessed for other urological conditions, including prostate cancer [50] . This advisory from the FDA emphasizes the need to monitor these patients for prostate cancer and to recognize the effect that these drugs have on PSA levels. One study that examined this issue involved observational follow-up of a randomized trial that compared one year of therapy with either finasteride or dutasteride in men on ongoing alpha blocker therapy; prostate volume and symptoms were monitored after discontinuation of therapy [51] . At one year after discontinuation, prostate volume had increased 19 to 21 percent, and symptom scores had worsened.
Combination therapy -Short-term therapy with combined alpha adrenergic antagonist and 5-alpha-reductase inhibitor therapy appears to be superior to either agent alone in men with BPH/LUTS and larger prostate glands [52] , but not in men with only moderate BPH [53] [54] [55] . Long-term combination therapy provides some added benefit even in men with moderate BPH [56] .
Short-term efficacy -In the Veterans Affairs Cooperative Study, 1229 men with BPH (mean peak urinary flow rate of 10.5 mL/sec) were randomly assigned to placebo, finasteride (5 mg/day), terazosin (10 mg/day), or both for one year [53] . Eligibility was based upon an American Urological Association symptom score of at least eight, a maximal urinary flow rate of no more than 15 mL/sec, and a residual urine volume of less than 300 mL; prostate size was not a factor. The following results were noted:
Terazosin lowered the symptom score and increased the peak urinary flow rate when compared with placebo.
Finasteride alone was no better than placebo.
The combination of finasteride and terazosin was no better than terazosin alone.
Similar findings were noted in the PREDICT trial in which 1095 men were randomly assigned to doxazosin, finasteride, or both for one year [55] . Doxazosin was more effective than finasteride or placebo for urinary symptoms and flow rate, but again, the combination was no more effective than doxazosin alone.
The mean prostate volume in these studies was approximately 37 mL [53, 55] , lower than the mean volume of approximately 60 mL in the Finasteride Study Group trial of finasteride alone [33] .
Long-term efficacy -Randomized trials have found that long-term combination therapy is superior to single-drug therapy for BPH symptoms [56, 57] .
The efficacy of long-term therapy was evaluated in the Medical Therapy of Prostatic Symptoms (MTOPS) trial, in which 3047 men with BPH were randomly assigned to receive doxazosin, (4 to 8 mg/day), finasteride (5 mg/day), combination therapy, or placebo [56] . The mean prostate volume was 36±20 mL. The patients were evaluated for symptomatic improvement and overall clinical disease progression, defined as an increase above baseline of at least four points in the AUA symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection. Long-term combination therapy lowered the risk of overall clinical progression of BPH significantly more than treatment with either drug alone. In addition, combination therapy or finasteride alone (but not doxazosin alone) reduced the risk of acute urinary retention and the need for invasive therapy.
At a mean follow-up of 4.5 years, the following results were seen (figure 3):
The risk of overall clinical progression was reduced to a similar degree by doxazosin and finasteride (39 and 34 percent, respectively, when compared to placebo).
Combination therapy reduced the risk of clinical progression by 66 percent, significantly greater than with either drug alone.
Symptom scores improved with all therapies, but to a greater degree with combined therapy.
Combination therapy or finasteride alone (but not doxazosin alone) reduced the risk of acute urinary retention and the need for invasive therapy.
The number needed to treat to prevent one instance of overall clinical progression was 8.4 for combination therapy, 13.7 for doxazosin, and 15.0 for finasteride.
Adverse effects were similar with combination therapy and monotherapy, with the exception of abnormal ejaculation, peripheral edema, and dyspnea, which were more common with combination therapy. Breast cancer risk was not increased in the finasteride-only or combination therapy groups.
A systematic review of the literature concluded that the combination of doxazosin and finasteride compared with doxazosin alone improves urinary symptoms in men with medium (25 to <40 mL) and large (>40 mL) prostates in the long-term [5] .
The four year CombAT study provides additional evidence that combination therapy is effective in men with larger prostates [57] . CombAT included men with BPH age 50 or older, an IPSS of at least 12, a prostate volume ≥30 mL, a PSA ≥1.5 to 10 ng/mL, and a maximum urinary flow rate >5mL and ≤15/second. Subjects were randomly assigned to therapy with dutasteride, tamsulosin, or both; there was no double placebo arm. Mean prostate volume in the 4844 men studied was approximately 55 mL.Combination therapy was superior to tamsulosin monotherapy, but not dutasteride monotherapy, in reducing the relative risk of acute urinary retention or BPH-related surgery. Combination therapy also was superior to either monotherapy in reducing BPH symptoms and the relative risk of BPH clinical progression ( figure 3) . However, more drug-related adverse events were seen with combination therapy than with monotherapy. Dutasteride alone or in combination with tamsulosin reduced the number of prostate biopsies by 40 percent and the relative risk of prostate cancer by 40 percent in men [58] .
Antimuscarinics -Some men with BPH/LUTS may also have frequency, urgency, and incontinence related to an overactive bladder. Bladder contractions are stimulated by acetylcholine effects on muscarinic receptors in smooth muscle of the bladder. A randomized trial in patients with moderate to severe obstructive symptoms, at least a moderate bother score, and urgency found that combination therapy with an anticholinergic agent with antimuscarinic effects (tolterodine) plus an alpha-1-adrenergic antagonist (tamsulosin) was reasonably safe with few episodes of urinary retention [59] . There was some suggestion that combination therapy was more effective than tamsulosin alone. Use of antimuscarinic agents should be restricted to men with low post-void residual volumes. (See "Lower urinary tract symptoms in men".)
Herbal therapies -Herbal therapies for BPH are commonly used in Europe; these remedies comprised 70 percent of spending for drug treatment of prostatism in Germany in 1997 [60] . Saw palmetto is approved by the German Commission E for stage I and II (mild to moderate) BPH. Two herbal extracts have officially been approved for the treatment of prostatism in France. No herbal therapies have been approved by the United States Food and Drug Administration for this purpose, although many men probably try these treatments. There is a substantial placebo effect associated with herbal therapy, as there is for most drugs used to treat BPH.
The data concerning efficacy of these therapies are conflicting. In systematic reviews of controlled trials, saw palmetto plant extract was as effective as finasteride in relieving the symptoms of prostate obstruction, although it did not decrease prostate volume [61] . A subsequent placebo-controlled trial found no evidence that saw palmetto was superior to placebo [62] . The evidence regarding the use of saw palmetto for BPH is discussed in detail separately. (See "Clinical use of saw palmetto".)
There is some evidence for efficacy of other agents as well. Systematic reviews have suggested the following:
The plant extract beta-sitosterol improved symptoms [63] .
Cernilton, which is prepared from the rye grass pollen, Secale cereale, has been evaluated in four clinical trials [64] . It improved symptoms, but did not affect urinary flow rates or residual urine or prostate volume.
Pygeum africanum is an extract of bark from an African plum tree. In a meta-analysis of 18 randomized controlled trials, active treatment improved symptoms two times more frequently than placebo and increased peak urinary flow rates 23 percent [65] .
Despite these systematic reviews, questions regarding safety and efficacy remain. As has been seen with saw palmetto (see "Clinical use of saw palmetto"), better designed trials do not always confirm the favorable results seen in less well-designed studies. Additionally, questions regarding standardization remain, particularly in the US. (See "Overview of herbal medicine and dietary supplements".)
Until additional studies of herbals are performed, we suggest using alpha-adrenergic antagonists and 5-alpha-reductase inhibitors rather than any of the above herbal therapies.
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Other -Observational studies suggested that phosphodiesterase-5 (PDE-5) inhibitors, primarily used as treatments for erectile dysfunction, were beneficial for BPH/LUTS [66] and led to subsequent clinical trials. In a meta-analysis of five randomized trials of men with LUTS secondary to BPH, PDE-5 inhibitors led to significant improvement in IPSS after ≥12 weeks of therapy, compared to placebo [67] . There was no significant difference in urodynamic parameters. A report found maximum urine flow rates as well as symptom scores to be improved by daily tadalafil [68] . The long-term effect of PDE-5 inhibitors in patients with BPH is unclear. Tadalafil is approved by the US Food and Drug Administration for use in BPH. It seems reasonable to discuss this option with men who have erectile dysfunction and mild or moderate symptoms of BPH. Daily dosing of tadalafil should not be prescribed in men with a creatinine clearance <30 mL/min.
As discussed above, PDE-5 inhibitors can potentiate the hypotensive effects of alpha-1-adrenergic antagonists. (See 'Side effects and interactions' above.)
There is some evidence that nonsteroidal antiinflammatory drugs (NSAIDs) can reduce symptoms of BPH/LUTS without improving urine flow rates [69] . Behavioral modifications may be helpful. These include avoiding fluids prior to bedtime or before going out, reducing consumption of mild diuretics such as caffeine and alcohol, and double voiding to empty the bladder more completely.
MODIFICATION OF THERAPY
A randomized trial found that, compared with men followed with watchful waiting alone, men given an educational intervention that included teaching of behavioral modifications were significantly less likely to experience treatment failure (mainly an increase in IPSS or requirement for medication) [70] .
ECONOMIC CONSIDERATIONS -Management of BPH/LUTS is estimated to cost more than $4 billion per year in the United States [71] . While the short-term costs of medical treatment are less than those of invasive treatment, many have questioned whether invasive treatment might be less expensive in the long run.
One study that examined this question in 970 privately insured men concluded that surgery was associated with higher costs and failure rates over a five year period, and medical therapy remained less expensive than invasive therapy over the long term [72] .
INFORMATION FOR PATIENTS -UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics."
The Basics patient education pieces are written in plain language, at the 5 th to 6 th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed.
These articles are written at the 10 th to 12 th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. 
SUMMARY AND RECOMMENDATIONS
Benign prostatic hyperplasia (BPH) becomes increasingly common as men age. BPH can lead to urinary symptoms that may benefit from medical or surgical treatment. However, many men with BPH are asymptomatic or have only mild symptoms and may not require therapy. Additionally, many men with symptoms will improve or stabilize without therapy. (See 'Introduction' above and 'Indications for therapy' above.)
In general, men who develop upper tract injury (eg, hydronephrosis, renal dysfunction) or lower tract injury (eg, urinary retention, recurrent infection, bladder decompensation) require invasive therapy. (See "Surgical and other invasive therapies of benign prostatic hyperplasia".)
We suggest that men with symptoms of BPH be instructed in behavior modifications (Grade 2B). These should be tailored to symptoms but may include avoiding fluids prior to bedtime or before going out, reducing consumption of mild diuretics such as caffeine and alcohol, and double voiding to empty the bladder more completely. (See 'Other strategies' above.)
Alpha-adrenergic antagonists provide immediate therapeutic benefits, while 5-alpha-reductase inhibitors require long-term treatment for efficacy. In most men with mild to moderate symptoms of BPH where those symptoms have a sufficient effect on quality of life that they desire therapy, we suggest initial treatment with an alpha-adrenergic antagonist alone (Grade 2A). In men with severe symptoms, those with a large prostate (>40 g), and in those who do not get an adequate response to maximal dose monotherapy with an alpha-adrenergic antagonist, we suggest combination treatment with an alpha-adrenergic antagonist and a 5-alpha-reductase inhibitor (Grade 2A). (See 'Combination therapy' above.)
The choice of alpha-adrenergic antagonist and 5-alpha-reductase inhibitor may be made on the basis of cost and side-effect profile. Tamsulosin, alfuzosin, and silodosin have less effect on blood pressure than either terazosin or doxazosin, and tamsulosin may further have slightly less effect on blood pressure than alfuzosin. (See 'Alpha-1-adrenergic antagonists' above.)
The two 5-alpha-reductase inhibitors, finasteride and dutasteride, appear to have similar efficacy and similar adverse effects. The agents are more effective in men with larger prostates, and their effects on acute urinary retention and reduction in need for invasive therapies require chronic treatment for more than a year. (See '5-alpha-reductase inhibitors' above.)
In men with low post-void residual urine volumes and irritative symptoms (eg, frequency, urgency) that persist during treatment with an alpha-adrenergic antagonist, we suggest treatment with an antimuscarinic agent (Grade 2B). Side effects may be minimized by using a low dose of short-acting medications (eg, tolterodine 1 mg twice daily). Alternatives include extendedrelease tolterodine, M3 selective drugs (eg, darifenacin, solifenacin), or quaternary amines (eg, trospium). (See 'Antimuscarinics' above and "Lower urinary tract symptoms in men".)
Use of UpToDate is subject to the Subscription and License Agreement.
GRAPHICS
Prevalence of benign prostatic hyperplasia pathology with age
Age-associated increase in pathologic evidence of benign prostatic hyperplasia in 1075 men at autopsy. The percentage with benign prostatic hyperplasia was determined during 10-year intervals from five different studies; the mean values are shown. Medical treatment of benign prostatic hyperplasia http://www.uptodate.com/contents/medical-treatment-of-benign-prostati...
Alpha-1 receptor antagonist for BPH*
Dose titration schedule to reduce orthostatic effects [1] Terazosin standard (appropriate for most patients) 
